Publications
Detailed Information
Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD
Cited 17 time in
Web of Science
Cited 18 time in Scopus
- Authors
- Issue Date
- 2009-02-20
- Publisher
- Wiley-Blackwell
- Citation
- Hum Psychopharmacol Clin Exp 2009 ;24(2):95-102.
- Keywords
- Administration, Oral ; Attention Deficit Disorder with Hyperactivity/*drug ; therapy/physiopathology ; Central Nervous System Stimulants/*administration & dosage ; Child ; Cognition Disorders/*drug therapy/etiology ; Delayed-Action Preparations ; Female ; Humans ; Linear Models ; Male ; Methylphenidate/*administration & dosage ; Neuropsychological Tests ; Reaction Time/drug effects
- Abstract
- OBJECTIVES: This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH-IR) to osmotic release oral system methylphenidate (OROS-MPH). METHODS: 102 children with attention-deficit/hyperactivity disorder (ADHD) participated in an open label, 28 day trial, performing neurocognitive test at baseline and at 28 days after the switch from MPH-IR to OROS-MPH. RESULTS: There were significant improvements in the commission error and the reaction time of both visual and auditory continuous performance tests (CPTs) at 28 days after switching from MPH-IR to OROS-MPH. A positive correlation was observed between the improvement in parent/caregiver-rated IOWA Conners total score (Delta IOWA) and the reduction in commission error (r = 0.3, p = 0.001) and reduction in reaction time variability (r = 0.3, p = 0.006) of visual CPT. In a linear regression model, the change in parent/caregiver-rated IOWA Conners scale total scores were significant predictors of change in commission error (beta = 0.3, p = 0.005, CI = 0.4-2.3, adjusted R(2) = 0.12) and RT variability (beta = 0.3, p = 0.004, CI = 0.5-2.4, adjusted R(2) = 0.09) of visual CPT. CONCLUSIONS: These data suggest that MPH-IR may be successfully switched to OROS-MPH treatment with associated improvements in neurocognitive performance. Large-scale controlled trials are needed to replicate these findings.
- ISSN
- 1099-1077 (Electronic)
0885-6222 (Print)
- Language
- English
- URI
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19226534
https://hdl.handle.net/10371/63327
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.